Cancer Research

{
  "result": " This tick’s most important insight is a razor-sharp strategic clarification: to break the current zero-evidence barrier in our colorectal cancer knowledge graph, the investigation must zero in on a single, testable nexus—the PCSK9 protein and its potentially divergent role in microsatellite-stable (MSS) versus microsatellite-unstable (MSI) tumors. Faced with 151 disconnected entities and no hardened relations, the AI determined that only an exact orthogonal triad—genetic instrument validation in plasma, tissue signal matching in tumors, and CRISPR dependency testing in cancer cells—can forge the first reliable edge. Three hypotheses were refined to reflect this surgical focus, but no new empirical relation was yet established, a reminder that in early-stage discovery, framing the precise question often precedes the answer.\n\nColorectal cancers are not uniform. Roughly 15 percent carry defects in their DNA “spell-checker” machinery, known as mismatch repair deficiency, which produces MSI tumors that behave and respond to therapy differently than their MSS counterparts. PCSK9 is best known for regulating cholesterol, yet emerging clues suggest it may also influence tumor biology through inflammation or survival pathways. The core challenge is determining whether genetically driven differences in PCSK9 protein levels truly alter colorectal cancer risk—and whether any such effect is specific to the MSI or MSS subtype rather than a blunt association across all cases.\n\nTo interrogate this, the AI designed a tightly scoped three-layer study. First, it identified genetic variants near PCSK9 that change its protein levels in blood, drawn from large proteomics studies (UKB-PPP and INTERVAL), intending to use them as natural experiments in Mendelian randomization. This approach leverages nature’s random assignment of genes to ask whether people born with higher or lower PCSK9 face different MSS or MSI cancer risks. Second, it prepared to test whether those same blood-based genetic signals appear in actual tumor tissue by colocalizing them with gene and protein expression data from CPTAC-CRC and TCGA. Third, it structured a DepMap CRISPR analysis to ask whether mismatch-repair-deficient cancer cells depend on PCSK9 to survive compared with repair-proficient cells.\n\nAs of this tick, the analysis has produced zero new empirical findings; the knowledge graph still holds 151 entities and zero hardened relations. The three updated hypotheses reflect refined assumptions about statistical modeling and instrument selection rather than confirmed biological associations. This is the honest texture of real science: the AI has mapped the precise experimental geometry required, but the harmonizations, colocalization posteriors, and dependency regressions remain to be executed. Whether PCSK9 is a causal risk factor, a synthetic-lethal vulnerability, or a neutral bystander in MSI colorectal cancer remains unproven and demands experimental validation.\n\nNext, the mission will run the full colocalization pipeline to see if plasma PCSK9 signals share a causal variant with tumor expression, complete the subtype-stratified Mendelian randomization across both proteomic discovery cohorts, and finalize the DepMap differential-essentiality models conditioned on mismatch repair status. The critical open question is directional alignment: if higher PCSK9 genetically predicts altered MSI risk, do MSI tumor cells simultaneously crave PCSK9 for survival, or can they tolerate its loss? Should all three orthogonal planes converge, they could reveal a subtype-specific therapeutic vulnerability. Until then, these hypotheses remain precisely that—hypotheses.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}